Suppression of malignant rhabdoid tumors through Chb‐M′‐mediated RUNX1 inhibition

Citations Over Time

Abstract

Malignant rhabdoid tumor (MRT) is a rare and highly aggressive pediatric malignancy primarily affecting infants and young children. Intensive multimodal therapies currently given to MRT patients are not sufficiently potent to control this highly malignant tumor. Therefore, additive or alternative therapy for these patients with a poor prognosis is necessary. We herein demonstrated that the inhibition of runt-related transcription factor 1 (RUNX1) by novel alkylating conjugated pyrrole-imidazole (PI) polyamides, which specifically recognize and bind to RUNX-binding DNA sequences, was highly effective in the treatment of rhabdoid tumor cell lines in vitro as well as in an in vivo mouse model. Therefore, suppression of RUNX1 activity may be a novel strategy for MRT therapy.

Related Papers

• → A comparison of in vivo and in vitro methods for determining availability of iron from meals(1981)109 cited
• → Studies on pharmacokinetics of sulfonated aluminum phthalocyanine in a transplantable mouse tumor by in vivo fluorescence(1993)8 cited
• → In vivo analysis of skin microcirculation in rats and mice(2008)2 cited
• → In Vivo Electroporation: A Convenient Method for Gene Transfer to Testicular Cells in Mice(1996)17 cited
• → Depletion of RUNX1/ETO in t(8:21) AML cells leads to genome-wide changes in transcription factor binding(2012)